BIOGNOSYS
15.3.2022 14:02:09 CET | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, and Kymera Therapeutics, a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD), announced today that they are broadly collaborating across preclinical studies and clinical trials.
Proteome editing with TPD is a new frontier of medicine, aimed at expanding the druggable proteome. Biognosys’ TrueSignature™ platform uniquely offers high-precision proteomic panels that provide actionable insights based on highly specific and sensitive, absolute quantification of pharmacodynamic and efficacy biomarkers. These custom panels allow Kymera to monitor and quantify protein degradation. The ease of transferability of the assays — from early discovery, across preclinical evaluation, to clinical development — enables integration into all stages of Kymera’s drug development process . The panels are developed and performed at Biognosys’ state-of-the-art facility, the largest high-end, GLP certified and GCP compliant mass spectrometry laboratory worldwide for large-scale proteomics contract research.
“Kymera’s novel approach to targeted protein degradation is a great example of the power of proteomics-enabled drug development,” said Kristina Beeler, Ph.D., Chief Business Officer of Biognosys . “We are glad to see the impact our TrueSignature platform is having, not only on the advancement of Kymera’s clinical trial programs, but also on patients’ lives.”
The current partnership between Kymera and Biognosys builds upon the longstanding scientific relationship between the two companies across early R&D, preclinical, and clinical settings across oncology and inflammation.
“Biognosys has been a valued partner as we continue to expand our clinical pipeline across a diverse set of diseases and indications,” said Nello Mainolfi, Ph.D., Co-Founder, President and CEO, Kymera Therapeutics . “The company’s high-precision custom proteomics panels enable us to monitor and quantify protein degradation across all aspects of drug development, including preclinical and clinical programs.”
About TrueSignature™
The Biognosys TrueSignature™ platform provides high-precision customizable proteomics panels for pharmacodynamic readouts and clinical biomarker monitoring.
Parallel Reaction Monitoring mass-spectrometry powers the platform, allowing complete customization and independence from affinity-based recognition and reagent availability. The TrueSignature™ panels offer an unprecedented level of multiplexing, enabling the simultaneous absolute quantification of up to 100 proteins.
TrueSignature panels can be developed within weeks and are available both as a standalone solution or an integrated solution, in which insights from TrueDiscovery studies guide the choice of proteins in the custom panel. The measurements are performed with unprecedented speed and throughput at Biognosys' state-of-the-art facility, the world's largest high-end GLP-certified and GCP-compliant mass spectrometry laboratory. For more information, visit truesignature.bio
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions, and making them widely available for pharmaceutical and biotechnology researchers, and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck Launches Exclusive Soccer Jersey Ticket Offer for Sports Fans in July9.7.2026 00:37:00 CEST | Press release
Guests can receive 15% off tickets purchased online when they wear their soccer team jersey at the ‘World’s Most Famous Building’ The Empire State Building Observation Deck (ESBOD) today announced a new, exclusive ticket offer for soccer fans who don their favorite team’s duds at the “World’s Most Famous Building” in anticipation of the tournament final. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708711923/en/ Empire State Building Observation Deck Launches Exclusive Soccer Jersey Ticket Offer for Sports Fans in July Guests who plan to wear their soccer jersey to the Empire State Building Observation Deck can purchase tickets online for 15 percent off to enjoy the immersive museum experience and New York City’s best views from the 86th and 102nd Floor Observation Decks. The limited-time offer is available only to guests who wear their soccer jersey on the day of their visit from now through July 31. “Whether they rep
New Esri Press Book Shows That GIS Can Transform the Entire Campus, Starting at the Classroom8.7.2026 23:33:00 CEST | Press release
The Spatial Edge Reveals How Spatial Thinking Drives Innovation, Efficiency, and Collaboration Across Higher Education Esri releases The Spatial Edge, a new book demonstrating how GIS technology unifies academic and operational functions across higher education institutions. The book highlights how universities use spatial thinking to enhance teaching, advance interdisciplinary research, and improve campus planning and operations across departments. Through real-world case studies, The Spatial Edge shows how GIS strengthens decision-making, connects disciplines, and supports institutions in solving complex campus and community challenges. Designed for administrators and educators, the guide emphasizes workforce readiness by equipping graduates with in-demand geospatial skills across diverse industries. Esri has released The Spatial Edge: The Strategic Advantage of GIS Skills Across Higher Education, a practical and accessible guide that demonstrates how geographic information system (G
Jefferies Financial Group Inc. Announces Pricing of €850,000,0004.500% Senior Notes Due 20338.7.2026 22:16:00 CEST | Press release
Jefferies Financial Group Inc. (NYSE: JEF) (“JFG”, “we” or “our”) today announced the pricing of its public offering of €850,000,000 aggregate principal amount of 4.500% Senior Notes due 2033 (the “Notes”) with an effective yield of 4.544%, maturing, July 15, 2033. The offering is expected to settle on July 15, 2026, subject to the satisfaction of customary closing conditions. Application is expected to be made for the Notes to be admitted to the Official List of the Irish Stock Exchange plc, trading as Euronext Dublin, and admitted to trading on the Global Exchange Market of Euronext Dublin; any listing is subject to approval by Euronext Dublin. JFG intends to use the net proceeds of the offering for general corporate purposes. Jefferies International Limited served as sole global co-ordinator and joint active book-runner for the offering of the Notes, Banco Santander, S.A., Citigroup Global Markets Limited, Natixis, SMBC Bank International plc and Société Générale served as joint act
KiddeFenwal Launches New Website and Information Hub8.7.2026 18:00:00 CEST | Press release
Enhanced digital platform reflects KiddeFenwal’s legacy, stature and growth trajectory in the fire suppression and safety controls industry KiddeFenwal, the global leader in the fire suppression and safety controls industry, today unveiled a revitalized website, designed to serve as a comprehensive information hub for fire industry practitioners and customers alike. The modernized platform includes features created specifically with the company’s global partners, OEMs and distributors in mind, including: Accelerated asset navigation, pointing users to critical safety documentation, design parameters and product specifications; Seamless solution mapping, helping users quickly locate fire suppression configurations by industry, from data centers to BESS applications to commercial kitchens; and Enhanced resource access, including streamlined pathways to connect with the company’s elite distributor network across 120 countries. It also provides information about the company’s three brands,
Dryad Networks Reaches XPRIZE Wildfire Finals Milestone, Demonstrating Autonomous Detection and Suppression of Wildfires in Alaska8.7.2026 17:00:00 CEST | Press release
Dryad Networks, the leader in ultra-early wildfire detection technology, today announced a major achievement in the finals of the Autonomous Wildfire Response track of XPRIZE Wildfire, a four-year, $11 million global competition accelerating new solutions to end destructive wildfires. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707802818/en/ The Silvaguard Suppression Drone can deliver a 100 liter liquid suppressant to autonomously suppress small wildfires detected by Silvanet Competing against just two other finalists selected from an original field of nearly 300 teams worldwide, Dryad successfully demonstrated the integrated capabilities of its Silvanet wildfire detection network and Silvaguard autonomous firefighting drone system during final testing in remote Alaska. The XPRIZE Wildfire finals challenged teams to autonomously detect and suppress a wildfire without any human intervention across a vast 1,000 square k
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom